Li Kong

Dr. Li Kong


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YSYu Song
Yu Song
QMQianqian Mao
Qianqian Mao
MZManling Zhou
Manling Zhou
CLChengJiang Liu
ChengJiang Liu
LKLi Kong
Li Kong
THTing Hu
Ting Hu
Objective: To evaluate the benefit of bevacizumab under the comprehensive treatment strategy and its advantages over other drugs, so as to provide reference for the formulation of clinical plans. Methods: As of October 1, 2022, the randomized controlled clinical trials of bevacizumab in combination with metastatic colorectal cancer published in PubMed, Cochrane Library and Medline databases were searched. The odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the short-term disease control effect and long-term survival of the treatment strategy. Results: 21 RCTs (6665 patients; 3356 patients in the experimental group and 3309 patients in the control group; average age, 55–75 years) were treated with bevacizumab as the experimental group for metastatic colorectal cancer. BEV has stronger anti-tumor activity than the single treatment scheme (OR = 1.30, 95% CI: 1.11–1.52). And Benefits of the BEV group were 0.73 (0.55, 0.96), 1.26 (0.71, 2.24), 1.63 (0.92, 2.87) and 0.07 (0.02, 0.25) compared with CET, VAN, CED and PAN respectively. The disease control of BEV combined therapy was better (OR = 1.36, 95% CI: 1.04–1.78). The same as compared with cediranib (OR = 1.94, 95% CI: 1.06–3.55). However, the long-term prognosis of BEV, including the overall survival (HRs = 0.98, 95% CI: 0.84–1.15) and progression-free survival (HRs = 1.05,95% CI: 0.97–1.13) were not prolonged. The survival benefits of cetuximab and panitumumab were not reflected. Conclusion: The addition of BEV can enhance the anti-tumor ability and disease control, while cetuximab and panitumumab may have stronger ability. However, it did not effectively improve the survival of patients. A more reasonable and effective treatment plan needs more clinical experimental support.

1 March 2019
Verified
Journal Article
Closed access
KFK-L Fan
K-L Fan
MLM-F Li
M-F Li
FCF. Cui
F. Cui
FFF. Feng
F. Feng
LKLi Kong
Li Kong
YLY. Liu
Y. Liu

30 November 2022 in Journal of International Medical Research
Verified
Journal Article
Open access
PWPeng Wang
Peng Wang
WCWei Cao
Wei Cao
HZHong Zhou
Hong Zhou
HZHuan Xin Zhang
Huan Xin Zhang
LZLunzhong Zhang
Lunzhong Zhang
LKLi Kong
Li Kong
Objective: To identify whether median nerve stimulation (MNS) may be a potential candidate for the treatment of consciousness disorders via a systematic review and meta-analysis. Methods: PubMed, Cochrane Library, China National Knowledge Infrastructure, Chinese VIP Information, Wanfang, and SinoMed databases were searched. Risk of bias was assessed using the Cochrane Collaboration’s tool. The Glasgow Coma Scale (GCS), Disability Rating Scale (DRS), electroencephalogram (EEG), days in the Intensive Care Unit (ICU), and cerebral blood flow measures were compared between the median nerve stimulation and control groups. The meta-analysis was conducted using Review Manager software. Results: We identified 2244 studies, of which 23 (with data from 1856 patients) qualified for the analysis. MNS improved GCS scores (mean difference [MD] = 2.15), EEG scores (MD = 1.61), cerebral mean blood flow velocity (MD = 4.23), and cerebral systolic blood flow velocity (MD = 10.51). Furthermore, it decreased DRS scores (MD = −1.77) and days in the ICU (MD = −2.02). The effects of MNS on GCS scores increased with longer treatments (1 week, MD = 1.03; 1 month, MD = 2.35) and were better with right MNS (right, MD = 2.36; bilateral, MD = 1.72). Conclusions: MNS may promote recovery from consciousness disorders.

10 April 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
DQDu Qinyuan
Du Qinyuan
QCQin Congcong
Qin Congcong
LGLi Guochen
Li Guochen
BQBi Qianyu
Bi Qianyu
ZSZhang Shuanglin
Zhang Shuanglin
LKLi Kong
Li Kong
Protein metabolic derangement is a hallmark of critical illness and contributes to adverse outcomes and delayed recovery. This narrative review synthesises current evidence on protein metabolism, requirement assessment, and supplementation strategies in critically ill adults, with emphasis on sepsis and severe burns as representative hypercatabolic phenotypes. Sepsis and major burns are characterised by accelerated skeletal muscle breakdown, negative nitrogen balance, and sustained functional impairment. Current guidelines generally support progressive enteral-first protein delivery after haemodynamic stabilisation, targeting at least 1.2–1.3 g/kg/day, whereas higher targets are more consistently justified in severe burns because of prolonged hypermetabolism, exudative losses, and wound-healing demands. However, randomised trials and meta-analyses do not show a uniform mortality benefit from higher protein provision, and very high early doses may be harmful in selected patients, particularly those with acute kidney injury or poor metabolic tolerance. Evidence for specific protein sources, functional amino acids, micronutrients, probiotics, and metabolic modulators remains heterogeneous. Future research should define phenotype-specific protein strategies using metabolic, structural, functional, and long-term patient-centred outcomes.

1 January 2023 in Open Chemistry
Verified
Journal Article
Open access
PDF file
LZLei Zhou
Lei Zhou
YYYanfen Yao
Yanfen Yao
QWQuanzhen Wang
Quanzhen Wang
PWPeng Wang
Peng Wang
SHShan Hong
Shan Hong
LKLi Kong
Li Kong
Sepsis is a common and deadly syndrome that despite all the progress in its control, the death rate caused by it is high. Sepsis is a serious problem that needs immediate attention and treatment. This infection, especially if it is caused by bacteria resistant to several drugs, causes high mortality. About two-thirds of sepsis cases occur in hospitalized patients. Several factors such as increasing the age of the population, increasing the duration of chronic diseases, high consumption of antibiotics and corticosteroids, use of mechanical devices and intravascular devices play a role in increasing its incidence. We herein demonstrate the biogenic procedure for the in situ immobilizing gold nanoparticles over lignin (Lig)-modified Fe3O4 magnetic nanoparticles mediated by Cydonia leaf extract (Fe3O4@Lig-Ag NPs) and its catalytic activity on the acetylation of alcohols using acetic anhydride and subsequent biological performances. The successful synthesis of Fe3O4@Lig-Ag NPs was assessed using an array of advanced techniques like field emission scanning electron microscopy, fourier transformed infrared spectroscopy, transmission electron microscopy EDX, elemental mapping, vibrating-sample magnetometer, and X-ray diffraction. Cecal ligation and puncture was used for inducing the sepsis model in rats. Several doses of Fe3O4@Lig-Ag NPs (45, 15, and 5 µg/kg) on oxidant–antioxidant, inflammatory mediators mRNA such as IL-1 and TNF-α, and its effects on the levels of expression were assessed in the kidney, liver, duodenum, lung, and stomach. When septic rats kidney, liver, duodenum, lung, and stomach were compared with those of the control group, it was found that Fe3O4@Lig-Ag NPs dose-dependent administration raised glutathione levels and superoxide dismutase activity and significantly reduced the levels of malondialdehyde. The Fe3O4@Lig-Ag NPs (45 µg/kg) indicated greater anti-oxidative effects than the 5 and 15 µg/kg doses for all the assessed parameters. In addition, the expression of TNF-α mRNA in the CLP + 45 µg/kg group was decreased in comparison with the control group. Fe3O4@Lig-Ag NPs reduced oxidative stress by enhancing the free radicals scavenging effects and supporting endogenous antioxidants. The Fe3O4@Lig-Ag NPs potent antioxidant property may be related to the cytokine cascade suppression during sepsis. The above findings offer that Fe3O4@Lig-Ag NPs administration may indicate a modern treatment for the inhibition of liver, kidney, lung, duodenum, and stomach tissues damage caused by septic conditions.

21 August 2023 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
PWPeng Wang
Peng Wang
DYDai Yuan
Dai Yuan
WWWeiwei Wang
Weiwei Wang
LZLei Zhou
Lei Zhou
LWLin Wang
Lin Wang
LKLi Kong
Li Kong